Compare PICS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PICS | ETON |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2018 |
| Metric | PICS | ETON |
|---|---|---|
| Price | $7.11 | $51.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $18.21 | ★ $71.50 |
| AVG Volume (30 Days) | ★ 1.0M | 376.5K |
| Earning Date | 11-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $52.12 | $87.26 |
| Revenue Next Year | $39.03 | $47.21 |
| P/E Ratio | ★ $29.44 | $127.66 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $7.07 | $14.27 |
| 52 Week High | $18.49 | $66.37 |
| Indicator | PICS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 29.05 | 44.67 |
| Support Level | N/A | $48.58 |
| Resistance Level | $11.87 | $57.00 |
| Average True Range (ATR) | 0.79 | 2.49 |
| MACD | -0.77 | 0.24 |
| Stochastic Oscillator | 0.68 | 34.62 |
PicS NV is a digital payments company. The company operates a peer-to-peer (P2P) transfer platform that enables individuals to send money via mobile devices. It provides digital wallets, instant payments (Pix), P2P transfers, credit cards, loans, investments, insurance, and SMB payment solutions. The company has four reportable segments: Consumer Banking, Small and Medium-Sized Businesses, Audiences and Ecosystem Integration, and Institutional. The majority of the company's revenue is derived from the Consumer Banking segment, which generates revenue from various transaction activities occurring in the digital wallet, such as Pix, peer-to-peer (P2P) transfers, and bill payments.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.